ClinicalTrials.gov
public full text
Public Domain
DENdritic Cell Immunotherapy for Mesothelioma
This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC alone.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Dendritic Cell-based Immunotherapy in Mesothelioma#125829
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma#448278
- Autologous Dendritic Cell Vaccination in Mesothelioma#307318
- Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma#140983
- Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma#127571
Record · ID 829552
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive